ReviewDeutsches Arzteblatt international2017
The Diagnosis and Treatment of Sjögren's Syndrome.
Review in Deutsches Arzteblatt international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 167 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
167 citing papers in PubMed, 4 syntheses or guidelines pooled it, 239 citations in OpenAlex.
- B-cell centrality dictates therapeutic efficacy across autoimmune diseases: a systematic review.Frontiers in immunology · 2026Pooled it
- Association of anti-Ro52 autoantibody with interstitial lung disease in autoimmune diseases: a systematic review and meta-analysis.BMJ open respiratory research · 2023Pooled it
- Diagnostic performance of serology against histologic assessment to diagnose Sjogren's syndrome: a systematic review.Clinical rheumatology · 2021Pooled it
- The Effectiveness and Safety of Total Glucosides of Paeony in Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2019Pooled it
- Varenicline Solution Nasal Spray for the Treatment of Dry Eye Disease in Sjogren's Disease: A Pilot Study.Clinical ophthalmology (Auckland, N.Z.) · 2025Trial
- Surgical advantage of modified labial salivary gland biopsy using chalazion forceps: a prospective randomized controlled study.Clinical and experimental medicine · 2024Trial
- Patient Journey, Disease Burden, Treatment Patterns, and the Impact of Delayed Diagnosis Among Patients With Sjögren's Disease: A Real-World US Survey.ACR open rheumatology · 2026Article
- Assessment of salivary gland involvement in primary Sjögren's syndrome using ultrasound viscoelasticity imaging.European radiology · 2026Article
- Discovery of biomarkers for primary Sj ögren's syndrome based on multi-omics data, construction of diagnostic models, and clinical correlation analysis.Arthritis research & therapy · 2026Article
- Investigating the potential of the Chinese herbal remedy SS-1 for the treatment of Sjögren's syndrome via the interleukin-17 signaling axis.Journal of traditional and complementary medicine · 2026Article
- mTOR signaling pathway in primary Sjögren's syndrome: Pathogenesis and potential therapeutic targets (Review).International journal of molecular medicine · 2026Review
- Article
- Exosomes derived from stem cells from apical papilla reduce Th17 cell differentiation and hyposalivation in a murine model of Sjögren's disease.BMC oral health · 2026Article
- Spotlight on Sjögren's: a patient perspective on burden of illness and unmet needs - results from a real-world survey.RMD open · 2026Article
- The overlap of ANCA associated vasculitis with Sjögren's syndrome in elderly male patient: a case report and literature review.Frontiers in medicine · 2026Article
- Platelet-Derived Growth Factor Isoform Imbalance Is Associated with Innate Inflammation and Corneal Epitheliopathy in Dry Eye Disease.Ophthalmic research · 2026Article
- Case Report: A case of rituximab for membranous nephropathy secondary to primary Sjogren's syndrome and literature review.Frontiers in immunology · 2026Review
- Immune-inflammatory and metabolic signatures for osteoporosis risk stratification in primary Sjögren's syndrome: development and internal validation of an interpretable machine-learning model.Frontiers in immunology · 2026Article
- Shengjiangsan Upregulates miR-328-3p to Inhibit MAP3K9 in the Treatment of Sjogren Disease: A Bioinformatics Analysis.Journal of inflammation research · 2026Article
- The Distinct Monocyte Subsets and Intercellular Communication in Primary Sjögren's Syndrome Revealed by Single-Cell RNA Sequencing.Journal of clinical immunology · 2025Article
107 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSjögren's syndrome is one of the more common inflammatory rheumatological diseases, with a prevalence of at least 0.4% in Germany.
methodsThis review is based on pertinent articles retrieved by a selective search in PubMed. Special attention is drawn to updated classification criteria and current treatment recommendations.
resultsSjögren's syndrome has a wide variety of presentations, ranging from the local involvement of exocrine glands with keratoconjunctivitis sicca and xerostomia (the leading signs of the disease) to the systemic, extraglandular involvement of multiple organs. Fatigue also markedly worsens the patients' quality of life. Serologic testing reveals antinuclear auto-antibodies (anti-Ro/ SSA and anti-La/SSB) as well as rheumatoid factors. The histological hallmark of the disease is focal lymphocytic infiltration in otherwise normal-appearing glandular acini. The disease also markedly elevates the risk of non-Hodgkin lymphoma of the B-cell series, which arises in about 5% of patients. Primary Sjögren's syndrome (pSS) differs from the secondary form (sSS), which appears in the setting of another autoimmune disease, particularly systemic lupus erythematosus (15-36%), rheumatoid arthritis (20-32%), and limited or progressive systemic sclerosis (11-24%). Disease-modifying therapy is reserved for patients with systemic involvement; there is limited evidence for its efficacy. Because of the complexity of this disease, some of its clinical manifestations may require interdisciplinary treatment.
conclusionThe main considerations in the interdisciplinary care of patients with Sjögren's disease are measures to improve quality of life, pharmacological and non-pharmacological treatments to keep disease activity in check, and management of the risk of lymphoma. Future therapeutic approaches must take the heterogeneity of the disease into account.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.